● Recruiting

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

Condition: Metastatic Breast Cancer · Breast Cancer Stage I · Breast Cancer Stage II · Sponsor: Forward Pharmaceuticals Co., Ltd.

PhasePhase 1/Phase 2

Planned participants196

Who can joinFemale, 18 Years to 75 Years

Healthy volunteersNo

About this study

This is a Study to Evaluate the Efficacy and Safety of Multiple Combination Therapies with FWD1802 in Subjects with ER-positive/HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer

This description comes directly from the study's public registry record.

Talk to the study team

Jinglin Xu · 18964533182 · xujl@forward-pharm.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fudan University Shanghai Cancer Center, Shanghai

Shanghai, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07002177